NIH Investigators Discover New Targets for Anti-Malarial Drugs
OCT 27, 2017 | CONTAGION® EDITORIAL STAFF
Armed with this new knowledge, the investigators were able to identify 3 experimental malaria drugs that may target plasmepsin X. The NIH mentioned one of these drugs, CWHM-117, which “has already been tested in a mouse model of malaria.” Knowing more about the role of plasmepsin X may help researchers to modify CWHM-117 to render it more effective. In addition, the NIH states that “parasites lacking the plasmepsins could potentially be used to screen candidate drugs to identify additional anti-malaria compounds.”
New antimalarial drugs can be a game-changer in the fight against this deadly disease. Recently, Jeremy Burrows, DPhil, MA, Vice President, Head of Discovery, Medicines for Malaria Venture, Switzerland, sat down with Contagion® to explain why.
The NIH study was conducted with funding provided by the National Institute of Allergy and Infectious Diseases, the National Heart, Lung, and Blood Institute, and the National Institute of General Medical Sciences.
The full study is published in the journal, Science.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512